MXPA04001890A - Peptidos derivados de caseina y sus usos en terapia. - Google Patents

Info

Publication number

MXPA04001890A

MXPA04001890A MXPA04001890A MXPA04001890A MXPA04001890A MX PA04001890 A MXPA04001890 A MX PA04001890A MX PA04001890 A MXPA04001890 A MX PA04001890A MX PA04001890 A MXPA04001890 A MX PA04001890A MX PA04001890 A MXPA04001890 A MX PA04001890A

Authority

MX

Mexico

Prior art keywords

casein

pharmaceutical composition

terminal portion

peptide derived

pharmaceutically acceptable

Prior art date

2001-08-30

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 616
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 521
• 235000021240 caseins Nutrition 0.000 title claims abstract description 516
• 239000005018 casein Substances 0.000 title claims abstract description 514
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 237
• 238000002560 therapeutic procedure Methods 0.000 title description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 92
• 201000010099 disease Diseases 0.000 claims abstract description 57
• 230000011132 hemopoiesis Effects 0.000 claims abstract description 32
• 208000036142 Viral infection Diseases 0.000 claims abstract description 23
• 230000009385 viral infection Effects 0.000 claims abstract description 23
• 230000003612 virological effect Effects 0.000 claims abstract description 22
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 17
• 208000014951 hematologic disease Diseases 0.000 claims abstract description 17
• 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 13
• 235000013336 milk Nutrition 0.000 claims abstract description 8
• 239000008267 milk Substances 0.000 claims abstract description 8
• 210000004080 milk Anatomy 0.000 claims abstract description 8
• 230000004936 stimulating effect Effects 0.000 claims abstract description 8
• 230000028993 immune response Effects 0.000 claims abstract description 7
• 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
• 230000003000 nontoxic effect Effects 0.000 claims abstract description 6
• 230000007170 pathology Effects 0.000 claims abstract description 6
• 230000002708 enhancing effect Effects 0.000 claims abstract 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 292
• 210000004027 cell Anatomy 0.000 claims description 248
• 239000004480 active ingredient Substances 0.000 claims description 196
• 239000003937 drug carrier Substances 0.000 claims description 187
• 238000000034 method Methods 0.000 claims description 174
• 108010041111 Thrombopoietin Proteins 0.000 claims description 128
• 102000036693 Thrombopoietin Human genes 0.000 claims description 128
• 230000001939 inductive effect Effects 0.000 claims description 108
• 210000004369 blood Anatomy 0.000 claims description 72
• 239000008280 blood Substances 0.000 claims description 72
• 230000035755 proliferation Effects 0.000 claims description 72
• 230000000694 effects Effects 0.000 claims description 69
• 238000011282 treatment Methods 0.000 claims description 51
• 210000001772 blood platelet Anatomy 0.000 claims description 47
• 238000010322 bone marrow transplantation Methods 0.000 claims description 42
• 210000001185 bone marrow Anatomy 0.000 claims description 38
• 206010043554 thrombocytopenia Diseases 0.000 claims description 38
• 230000001400 myeloablative effect Effects 0.000 claims description 37
• 230000007812 deficiency Effects 0.000 claims description 35
• 230000004663 cell proliferation Effects 0.000 claims description 34
• 230000003394 haemopoietic effect Effects 0.000 claims description 34
• 230000001965 increasing effect Effects 0.000 claims description 32
• 208000035475 disorder Diseases 0.000 claims description 31
• 210000002540 macrophage Anatomy 0.000 claims description 29
• 201000010000 Agranulocytosis Diseases 0.000 claims description 28
• 206010018687 Granulocytopenia Diseases 0.000 claims description 28
• 206010033661 Pancytopenia Diseases 0.000 claims description 28
• 210000005259 peripheral blood Anatomy 0.000 claims description 27
• 239000011886 peripheral blood Substances 0.000 claims description 27
• 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 26
• 208000023275 Autoimmune disease Diseases 0.000 claims description 24
• 208000031886 HIV Infections Diseases 0.000 claims description 24
• 210000002381 plasma Anatomy 0.000 claims description 24
• 206010012601 diabetes mellitus Diseases 0.000 claims description 22
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 22
• 210000004698 lymphocyte Anatomy 0.000 claims description 22
• 208000030507 AIDS Diseases 0.000 claims description 21
• 208000015181 infectious disease Diseases 0.000 claims description 19
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 19
• 108090000394 Erythropoietin Proteins 0.000 claims description 18
• 102000003951 Erythropoietin Human genes 0.000 claims description 18
• 206010018473 Glycosuria Diseases 0.000 claims description 18
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
• 230000004069 differentiation Effects 0.000 claims description 18
• 229940105423 erythropoietin Drugs 0.000 claims description 18
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 16
• 238000002512 chemotherapy Methods 0.000 claims description 16
• 210000004443 dendritic cell Anatomy 0.000 claims description 16
• 230000010437 erythropoiesis Effects 0.000 claims description 15
• 208000037357 HIV infectious disease Diseases 0.000 claims description 14
• 210000000601 blood cell Anatomy 0.000 claims description 14
• 239000003795 chemical substances by application Substances 0.000 claims description 14
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
• 210000000440 neutrophil Anatomy 0.000 claims description 14
• 230000002093 peripheral effect Effects 0.000 claims description 14
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 13
• 230000000735 allogeneic effect Effects 0.000 claims description 13
• 230000002489 hematologic effect Effects 0.000 claims description 13
• 238000011127 radiochemotherapy Methods 0.000 claims description 12
• 230000015572 biosynthetic process Effects 0.000 claims description 11
• 208000018138 dendritic cell deficiency Diseases 0.000 claims description 11
• 230000001363 autoimmune Effects 0.000 claims description 10
• 208000018706 hematopoietic system disease Diseases 0.000 claims description 10
• 201000001421 hyperglycemia Diseases 0.000 claims description 9
• 208000013544 Platelet disease Diseases 0.000 claims description 8
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
• 241000700605 Viruses Species 0.000 claims description 8
• 208000032467 Aplastic anaemia Diseases 0.000 claims description 7
• 208000026278 immune system disease Diseases 0.000 claims description 6
• 208000035143 Bacterial infection Diseases 0.000 claims description 5
• 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 5
• 206010065553 Bone marrow failure Diseases 0.000 claims description 5
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
• 210000000987 immune system Anatomy 0.000 claims description 5
• 238000001959 radiotherapy Methods 0.000 claims description 5
• 210000002443 helper t lymphocyte Anatomy 0.000 claims description 4
• 238000002513 implantation Methods 0.000 claims description 3
• 238000002054 transplantation Methods 0.000 claims description 3
• 101150064066 CTSL gene Proteins 0.000 claims description 2
• 208000037913 T-cell disorder Diseases 0.000 claims description 2
• 208000035473 Communicable disease Diseases 0.000 claims 8
• 241000711573 Coronaviridae Species 0.000 claims 7
• 230000001524 infective effect Effects 0.000 claims 7
• 241000315672 SARS coronavirus Species 0.000 claims 4
• 230000002503 metabolic effect Effects 0.000 claims 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 101100321409 Rattus norvegicus Zdhhc23 gene Proteins 0.000 claims 1
• 239000012678 infectious agent Substances 0.000 claims 1
• 102000011632 Caseins Human genes 0.000 description 471
• 108010076119 Caseins Proteins 0.000 description 470
• 241000282414 Homo sapiens Species 0.000 description 66
• 241000699670 Mus sp. Species 0.000 description 60
• 238000002360 preparation method Methods 0.000 description 46
• 239000000203 mixture Substances 0.000 description 40
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 36
• 239000003814 drug Substances 0.000 description 33
• 229940024606 amino acid Drugs 0.000 description 28
• 235000001014 amino acid Nutrition 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 25
• 238000011534 incubation Methods 0.000 description 25
• 108020003175 receptors Proteins 0.000 description 25
• 102000005962 receptors Human genes 0.000 description 25
• 210000002568 pbsc Anatomy 0.000 description 23
• 239000000427 antigen Substances 0.000 description 22
• 102000036639 antigens Human genes 0.000 description 22
• 108091007433 antigens Proteins 0.000 description 22
• 230000000638 stimulation Effects 0.000 description 20
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 19
• 210000002798 bone marrow cell Anatomy 0.000 description 18
• 239000004471 Glycine Substances 0.000 description 17
• 210000003593 megakaryocyte Anatomy 0.000 description 17
• -1 triangles Chemical compound 0.000 description 16
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 239000002609 medium Substances 0.000 description 15
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 13
• 239000012636 effector Substances 0.000 description 13
• 102100037904 CD9 antigen Human genes 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 12
• 108090000695 Cytokines Proteins 0.000 description 12
• 210000003743 erythrocyte Anatomy 0.000 description 12
• 238000010348 incorporation Methods 0.000 description 12
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 10
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 10
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 10
• 210000003714 granulocyte Anatomy 0.000 description 10
• 210000000265 leukocyte Anatomy 0.000 description 10
• 210000000822 natural killer cell Anatomy 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 9
• 206010028980 Neoplasm Diseases 0.000 description 9
• 201000011510 cancer Diseases 0.000 description 9
• 210000004700 fetal blood Anatomy 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 229940090044 injection Drugs 0.000 description 9
• 239000002953 phosphate buffered saline Substances 0.000 description 9
• 230000002265 prevention Effects 0.000 description 9
• 210000000130 stem cell Anatomy 0.000 description 9
• 230000004083 survival effect Effects 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 241001529936 Murinae Species 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 238000004128 high performance liquid chromatography Methods 0.000 description 8
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
• 229910002092 carbon dioxide Inorganic materials 0.000 description 7
• 238000004113 cell culture Methods 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 229940107161 cholesterol Drugs 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 235000013365 dairy product Nutrition 0.000 description 6
• 239000010432 diamond Substances 0.000 description 6
• 235000005911 diet Nutrition 0.000 description 6
• 230000037213 diet Effects 0.000 description 6
• 239000012634 fragment Substances 0.000 description 6
• 238000003306 harvesting Methods 0.000 description 6
• 210000005260 human cell Anatomy 0.000 description 6
• 238000010255 intramuscular injection Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 210000004180 plasmocyte Anatomy 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 231100000419 toxicity Toxicity 0.000 description 6
• 230000001988 toxicity Effects 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 102000014171 Milk Proteins Human genes 0.000 description 5
• 108010011756 Milk Proteins Proteins 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 239000012228 culture supernatant Substances 0.000 description 5
• 230000029087 digestion Effects 0.000 description 5
• 230000000925 erythroid effect Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 239000007927 intramuscular injection Substances 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 230000035899 viability Effects 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• 241000700198 Cavia Species 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 102000001554 Hemoglobins Human genes 0.000 description 4
• 108010054147 Hemoglobins Proteins 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 239000012980 RPMI-1640 medium Substances 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 238000004820 blood count Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000001516 cell proliferation assay Methods 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 210000004748 cultured cell Anatomy 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 238000010166 immunofluorescence Methods 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 235000021239 milk protein Nutrition 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 235000018102 proteins Nutrition 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 230000002797 proteolythic effect Effects 0.000 description 4
• 238000007363 ring formation reaction Methods 0.000 description 4
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 229940104230 thymidine Drugs 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 208000034423 Delivery Diseases 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 208000007541 Preleukemia Diseases 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 229940067621 aminobutyrate Drugs 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000007446 glucose tolerance test Methods 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 102000013415 peroxidase activity proteins Human genes 0.000 description 3
• 108040007629 peroxidase activity proteins Proteins 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000002203 pretreatment Methods 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• YAXAFCHJCYILRU-RXMQYKEDSA-N (2r)-2-(methylamino)-4-methylsulfanylbutanoic acid Chemical compound CN[C@@H](C(O)=O)CCSC YAXAFCHJCYILRU-RXMQYKEDSA-N 0.000 description 2
• SCIFESDRCALIIM-SECBINFHSA-N (2r)-2-(methylazaniumyl)-3-phenylpropanoate Chemical compound CN[C@@H](C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-SECBINFHSA-N 0.000 description 2
• WTDHSXGBDZBWAW-QMMMGPOBSA-N (2s)-2-[cyclohexyl(methyl)azaniumyl]propanoate Chemical compound OC(=O)[C@H](C)N(C)C1CCCCC1 WTDHSXGBDZBWAW-QMMMGPOBSA-N 0.000 description 2
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
• 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 2
• FOUZISDNESEYLX-UHFFFAOYSA-N 2-(2-hydroxyethylazaniumyl)acetate Chemical compound OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 description 2
• HEPOIJKOXBKKNJ-UHFFFAOYSA-N 2-(propan-2-ylazaniumyl)acetate Chemical compound CC(C)NCC(O)=O HEPOIJKOXBKKNJ-UHFFFAOYSA-N 0.000 description 2
• OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
• GAUBNQMYYJLWNF-UHFFFAOYSA-N 3-(Carboxymethylamino)propanoic acid Chemical compound OC(=O)CCNCC(O)=O GAUBNQMYYJLWNF-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 108090000746 Chymosin Proteins 0.000 description 2
• CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102000015779 HDL Lipoproteins Human genes 0.000 description 2
• 108010010234 HDL Lipoproteins Proteins 0.000 description 2
• 208000023661 Haematological disease Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
• QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• WRUZLCLJULHLEY-UHFFFAOYSA-N N-(p-hydroxyphenyl)glycine Chemical compound OC(=O)CNC1=CC=C(O)C=C1 WRUZLCLJULHLEY-UHFFFAOYSA-N 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 108010077895 Sarcosine Proteins 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 238000011316 allogeneic transplantation Methods 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000000923 atherogenic effect Effects 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 210000003995 blood forming stem cell Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 150000007942 carboxylates Chemical class 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 229940080701 chymosin Drugs 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000005757 colony formation Effects 0.000 description 2
• 239000000306 component Substances 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 230000001066 destructive effect Effects 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000000267 erythroid cell Anatomy 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 229940012952 fibrinogen Drugs 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 230000035780 glucosuria Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229960001913 mecysteine Drugs 0.000 description 2
• 210000002894 multi-fate stem cell Anatomy 0.000 description 2
• GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 2
• 210000004898 n-terminal fragment Anatomy 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 230000000149 penetrating effect Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 229960001639 penicillamine Drugs 0.000 description 2
• 210000004976 peripheral blood cell Anatomy 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 238000002616 plasmapheresis Methods 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 238000011886 postmortem examination Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 238000011191 terminal modification Methods 0.000 description 2
• 239000010936 titanium Substances 0.000 description 2
• 231100000820 toxicity test Toxicity 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• XLBVNMSMFQMKEY-SCSAIBSYSA-N (2r)-2-(methylamino)pentanedioic acid Chemical compound CN[C@@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-SCSAIBSYSA-N 0.000 description 1
• CYZKJBZEIFWZSR-ZCFIWIBFSA-N (2r)-3-(1h-imidazol-5-yl)-2-(methylamino)propanoic acid Chemical compound CN[C@@H](C(O)=O)CC1=CN=CN1 CYZKJBZEIFWZSR-ZCFIWIBFSA-N 0.000 description 1
• AKCRVYNORCOYQT-RXMQYKEDSA-N (2r)-3-methyl-2-(methylazaniumyl)butanoate Chemical compound C[NH2+][C@H](C(C)C)C([O-])=O AKCRVYNORCOYQT-RXMQYKEDSA-N 0.000 description 1
• KSZFSNZOGAXEGH-SCSAIBSYSA-N (2r)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@@H](C(O)=O)CCC(N)=O KSZFSNZOGAXEGH-SCSAIBSYSA-N 0.000 description 1
• OZRWQPFBXDVLAH-RXMQYKEDSA-N (2r)-5-amino-2-(methylamino)pentanoic acid Chemical compound CN[C@@H](C(O)=O)CCCN OZRWQPFBXDVLAH-RXMQYKEDSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• LDUWTIUXPVCEQF-LURJTMIESA-N (2s)-2-(cyclopentylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1CCCC1 LDUWTIUXPVCEQF-LURJTMIESA-N 0.000 description 1
• NVXKJPGRZSDYPK-JTQLQIEISA-N (2s)-2-(methylamino)-4-phenylbutanoic acid Chemical compound CN[C@H](C(O)=O)CCC1=CC=CC=C1 NVXKJPGRZSDYPK-JTQLQIEISA-N 0.000 description 1
• FPDYKABXINADKS-LURJTMIESA-N (2s)-2-(methylazaniumyl)hexanoate Chemical compound CCCC[C@H](NC)C(O)=O FPDYKABXINADKS-LURJTMIESA-N 0.000 description 1
• HCPKYUNZBPVCHC-YFKPBYRVSA-N (2s)-2-(methylazaniumyl)pentanoate Chemical compound CCC[C@H](NC)C(O)=O HCPKYUNZBPVCHC-YFKPBYRVSA-N 0.000 description 1
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
• KWWFNGCKGYUCLC-RXMQYKEDSA-N (2s)-3,3-dimethyl-2-(methylamino)butanoic acid Chemical compound CN[C@H](C(O)=O)C(C)(C)C KWWFNGCKGYUCLC-RXMQYKEDSA-N 0.000 description 1
• AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 description 1
• XKZCXMNMUMGDJG-AWEZNQCLSA-N (2s)-3-[(6-acetylnaphthalen-2-yl)amino]-2-aminopropanoic acid Chemical compound C1=C(NC[C@H](N)C(O)=O)C=CC2=CC(C(=O)C)=CC=C21 XKZCXMNMUMGDJG-AWEZNQCLSA-N 0.000 description 1
• LNSMPSPTFDIWRQ-VKHMYHEASA-N (2s)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-VKHMYHEASA-N 0.000 description 1
• KSZFSNZOGAXEGH-BYPYZUCNSA-N (2s)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@H](C(O)=O)CCC(N)=O KSZFSNZOGAXEGH-BYPYZUCNSA-N 0.000 description 1
• OZRWQPFBXDVLAH-YFKPBYRVSA-N (2s)-5-amino-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CCCN OZRWQPFBXDVLAH-YFKPBYRVSA-N 0.000 description 1
• RHMALYOXPBRJBG-WXHCCQJTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s,3r)-2-[[(2s)-2-[[2-[[2-[[(2r)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]- Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RHMALYOXPBRJBG-WXHCCQJTSA-N 0.000 description 1
• FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
• YSFQIJDACSFIOH-UHFFFAOYSA-N 2,2-diaminopropanoic acid Chemical compound CC(N)(N)C(O)=O YSFQIJDACSFIOH-UHFFFAOYSA-N 0.000 description 1
• PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
• DHGYLUFLENKZHH-UHFFFAOYSA-N 2-(3-aminopropylamino)acetic acid Chemical compound NCCCNCC(O)=O DHGYLUFLENKZHH-UHFFFAOYSA-N 0.000 description 1
• IVCQRTJVLJXKKJ-UHFFFAOYSA-N 2-(butan-2-ylazaniumyl)acetate Chemical compound CCC(C)NCC(O)=O IVCQRTJVLJXKKJ-UHFFFAOYSA-N 0.000 description 1
• KQLGGQARRCMYGD-UHFFFAOYSA-N 2-(cyclobutylamino)acetic acid Chemical compound OC(=O)CNC1CCC1 KQLGGQARRCMYGD-UHFFFAOYSA-N 0.000 description 1
• DICMQVOBSKLBBN-UHFFFAOYSA-N 2-(cyclodecylamino)acetic acid Chemical compound OC(=O)CNC1CCCCCCCCC1 DICMQVOBSKLBBN-UHFFFAOYSA-N 0.000 description 1
• OQMYZVWIXPPDDE-UHFFFAOYSA-N 2-(cyclohexylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCC1 OQMYZVWIXPPDDE-UHFFFAOYSA-N 0.000 description 1
• PNKNDNFLQNMQJL-UHFFFAOYSA-N 2-(cyclooctylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCCCC1 PNKNDNFLQNMQJL-UHFFFAOYSA-N 0.000 description 1
• DXQCCQKRNWMECV-UHFFFAOYSA-N 2-(cyclopropylazaniumyl)acetate Chemical compound OC(=O)CNC1CC1 DXQCCQKRNWMECV-UHFFFAOYSA-N 0.000 description 1
• PRVOMNLNSHAUEI-UHFFFAOYSA-N 2-(cycloundecylamino)acetic acid Chemical compound OC(=O)CNC1CCCCCCCCCC1 PRVOMNLNSHAUEI-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• 101800000535 3C-like proteinase Proteins 0.000 description 1
• 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
• GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical class C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
• FVBZXNSRIDVYJS-UHFFFAOYSA-N 6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C1CCCN1C(=O)C(N)CCCN=C(N)N FVBZXNSRIDVYJS-UHFFFAOYSA-N 0.000 description 1
• 229940124718 AIDS vaccine Drugs 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 102100035606 Beta-casein Human genes 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 238000011749 CBA mouse Methods 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• 241000282826 Camelus Species 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 206010065305 Cancer in remission Diseases 0.000 description 1
• 241000283705 Capra hircus Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 241000283153 Cetacea Species 0.000 description 1
• 244000089742 Citrus aurantifolia Species 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
• 229930195711 D-Serine Natural products 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
• 229930028154 D-arginine Natural products 0.000 description 1
• 125000000028 D-cysteine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(S[H])([H])[H] 0.000 description 1
• 229930182847 D-glutamic acid Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
• 229930195715 D-glutamine Natural products 0.000 description 1
• HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
• 229930195721 D-histidine Natural products 0.000 description 1
• 229930182845 D-isoleucine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
• 229930182819 D-leucine Natural products 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
• 229930182818 D-methionine Natural products 0.000 description 1
• COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
• 229930182832 D-phenylalanine Natural products 0.000 description 1
• 229930182820 D-proline Natural products 0.000 description 1
• AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
• 229930182822 D-threonine Natural products 0.000 description 1
• OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
• 229930195709 D-tyrosine Natural products 0.000 description 1
• KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
• 229930182831 D-valine Natural products 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 206010018612 Gonorrhoea Diseases 0.000 description 1
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 101000947120 Homo sapiens Beta-casein Proteins 0.000 description 1
• 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101000946053 Homo sapiens Lysosomal-associated transmembrane protein 4A Proteins 0.000 description 1
• 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
• LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000001911 Idiopathic aplastic anemia Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102100034728 Lysosomal-associated transmembrane protein 4A Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
• VKZGJEWGVNFKPE-UHFFFAOYSA-N N-Isobutylglycine Chemical compound CC(C)CNCC(O)=O VKZGJEWGVNFKPE-UHFFFAOYSA-N 0.000 description 1
• SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
• NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
• GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
• YAXAFCHJCYILRU-YFKPBYRVSA-N N-methyl-L-methionine Chemical compound C[NH2+][C@H](C([O-])=O)CCSC YAXAFCHJCYILRU-YFKPBYRVSA-N 0.000 description 1
• SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
• AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
• CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
• 101150054880 NASP gene Proteins 0.000 description 1
• 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000283898 Ovis Species 0.000 description 1
• 238000006610 Payne rearrangement reaction Methods 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
• 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
• 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101100008569 Rattus norvegicus Cst4 gene Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 206010043275 Teratogenicity Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 201000004208 acquired thrombocytopenia Diseases 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• DLAMVQGYEVKIRE-UHFFFAOYSA-N alpha-(methylamino)isobutyric acid Chemical compound CNC(C)(C)C(O)=O DLAMVQGYEVKIRE-UHFFFAOYSA-N 0.000 description 1
• 238000010976 amide bond formation reaction Methods 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000002052 anaphylactic effect Effects 0.000 description 1
• 230000002744 anti-aggregatory effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000036436 anti-hiv Effects 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 239000003173 antianemic agent Substances 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 239000010836 blood and blood product Substances 0.000 description 1
• 238000009640 blood culture Methods 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 229940125691 blood product Drugs 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 235000001465 calcium Nutrition 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 229940021722 caseins Drugs 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 108091092356 cellular DNA Proteins 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229940099352 cholate Drugs 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 235000021277 colostrum Nutrition 0.000 description 1
• 210000003022 colostrum Anatomy 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 235000020247 cow milk Nutrition 0.000 description 1
• 239000012531 culture fluid Substances 0.000 description 1
• 230000000120 cytopathologic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000004040 defense response to microbe Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 235000021186 dishes Nutrition 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 238000013230 female C57BL/6J mice Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000010437 gem Substances 0.000 description 1
• 238000011773 genetically engineered mouse model Methods 0.000 description 1
• 230000004313 glare Effects 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 229940093181 glucose injection Drugs 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 230000002641 glycemic effect Effects 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 208000001786 gonorrhea Diseases 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940116886 human interleukin-6 Drugs 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
• 208000003669 immune deficiency disease Diseases 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000031891 intestinal absorption Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• POPBCYBNIJKVES-XAFWQQJMSA-N isracidin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C1=CN=CN1 POPBCYBNIJKVES-XAFWQQJMSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229940078547 methylserine Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 235000021590 normal diet Nutrition 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000003075 phytoestrogen Substances 0.000 description 1
• 108010086662 phytohemagglutinin-M Proteins 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000000135 prohibitive effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000009331 sowing Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 238000007801 sublethal irradiation Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000012134 supernatant fraction Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 231100000378 teratogenic Toxicity 0.000 description 1
• 230000003390 teratogenic effect Effects 0.000 description 1
• 231100000211 teratogenicity Toxicity 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 229940035024 thioglycerol Drugs 0.000 description 1
• 230000003582 thrombocytopenic effect Effects 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• 230000035921 thrombopoiesis Effects 0.000 description 1
• 230000001361 thrombopoietic effect Effects 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 229940045136 urea Drugs 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000002966 varnish Substances 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 235000008939 whole milk Nutrition 0.000 description 1
• 235000021249 α-casein Nutrition 0.000 description 1